Patents by Inventor Dunja UROSEV
Dunja UROSEV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965019Abstract: Provided herein are stabilized chimeric Fabs derived from a parent chimeric Fab having a lambda light chain. The stabilized chimeric Fabs comprise an immunoglobulin heavy chain polypeptide construct from the parent chimeric Fab, having a CH1 sequence and a VH sequence, as well as a Vlambda-Ckappa chimeric light chain construct. The Vlambda sequence of the chimeric light chain construct corresponds to that of the parent chimeric Fab, and comprises one or more stabilizing amino acid modifications that increase the thermal stability of the stabilized chimeric Fab compared to the parent chimeric Fab. The stabilized Fabs are useful as therapeutic polypeptides, or can be used to prepare antibody constructs in other formats. The stabilized chimeric Fabs may also be useful generally to increase the stability of antibodies having lambda light chains.Type: GrantFiled: June 29, 2018Date of Patent: April 23, 2024Assignee: ZYMEWORKS BC INC.Inventors: Dunja Urosev, Yang-Chieh Chou
-
Publication number: 20230265202Abstract: Described herein are antibody constructs comprising a 4- 1BB binding domain and an anti-Folate Receptor a (FRa) antigen- binding domain, wherein the 4-1BB-binding domain and the FR? antigen-binding domain are linked directly or indirectly to a scaffold. The scaffold may be an Fc construct with modifications that reduce its ability to mediate effector function. The antibody constructs are used in the treatment of a subject having cancer.Type: ApplicationFiled: April 9, 2021Publication date: August 24, 2023Inventors: Daniel T. PATTON, Lee FREIBURGER, Thomas SPRETER VON KREUDENSTEIN, David M. MILLS, Gesa VOLKERS, Dunja UROSEV, Zhuang DUAN, Elizabeth HALVORSEN, Harsh PRATAP, Brandon CLAVETTE, Anna VON ROSSUM, Patricia ZWIERZCHOWSKI, Peter Wing Yiu CHAN, Danny CHUI, Sylwia JANCOWSKI, Sukhbir Singh KANG, Grant Raymond Wickman
-
Publication number: 20230052369Abstract: Described herein are antibody constructs comprising a 41-1BB binding domain and an antigen-binding domain that binds to a tumor-associated antigen (TAA), wherein the 4-1BB-binding domain and the TAA antigen-binding domain are linked directly or indirectly to a scaffold. The scaffold may be an Fc construct with modifications that reduce its ability to mediate effector function.Type: ApplicationFiled: April 9, 2021Publication date: February 16, 2023Inventors: Daniel T. PATTON, David M. MILLS, Thomas SPRETER VON KREUDENSTEIN, Gesa VOLKERS, Dunja UROSEV, Lee FREIBURGER, Zhuang DUAN, Elizabeth HALVORSEN, Harsh PRATAP, Brandon CLAVETTE, Anna VON ROSSUM, Duncan BROWMAN, Peter Wing Yiu CHAN, Danny CHUI, Robert William GENE, Sylwia JANCOWSKI, Sukhbir Singh KANG, Patricia ZWIERZCHOWSKI
-
Publication number: 20220251242Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: February 25, 2022Publication date: August 11, 2022Inventors: Mario SANCHES, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A.L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
-
Publication number: 20220227840Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: January 24, 2022Publication date: July 21, 2022Inventors: Adam Louis CORPER, Dunja UROSEV, Stacey A.L. TOM-YEW, Dustin Weyland Blue BLEILE, Thomas SPRETER VON KREUDENSTEIN, Surjit DIXIT, Paula Irene LARIO, Mario SANCHES
-
Patent number: 11306156Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: GrantFiled: May 29, 2015Date of Patent: April 19, 2022Assignee: ZYMEWORKS INC.Inventors: Mario Sanches, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A. L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
-
Patent number: 11286293Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: GrantFiled: September 5, 2018Date of Patent: March 29, 2022Assignee: ZYMEWORKS, INC.Inventors: Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Publication number: 20210355239Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.Type: ApplicationFiled: April 27, 2021Publication date: November 18, 2021Inventors: Dunja UROSEV, Stacey A.L. TOM-YEW, Leonard G. PRESTA, Mario SANCHES
-
Patent number: 11161915Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.Type: GrantFiled: October 7, 2016Date of Patent: November 2, 2021Assignee: ZYMEWORKS INC.Inventors: Dunja Urosev, Stacey A. L. Tom-Yew, Leonard G. Presta, Mario Sanches
-
Publication number: 20210309760Abstract: Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and/or CL domains, amino acid modifications in the VH and/or VL domains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: June 9, 2021Publication date: October 7, 2021Inventors: Adam Louis Corper, Dunja Urosev, Stacey A.L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Patent number: 11078296Abstract: Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and/or CL domains, amino acid modifications in the VH and/or VL domains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.Type: GrantFiled: February 14, 2018Date of Patent: August 3, 2021Assignee: ZYMEWORKS INC.Inventors: Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Publication number: 20200308270Abstract: Provided herein are stabilized chimeric Fabs derived from a parent chimeric Fab having a lambda light chain. The stabilized chimeric Fabs comprise an immunoglobulin heavy chain polypeptide construct from the parent chimeric Fab, having a CH1 sequence and a VH sequence, as well as a Vlambda-Ckappa chimeric light chain construct. The Vlambda sequence of the chimeric light chain construct corresponds to that of the parent chimeric Fab, and comprises one or more stabilizing amino acid modifications that increase the thermal stability of the stabilized chimeric Fab compared to the parent chimeric Fab. The stabilized Fabs are useful as therapeutic polypeptides, or can be used to prepare antibody constructs in other formats. The stabilized chimeric Fabs may also be useful generally to increase the stability of antibodies having lambda light chains.Type: ApplicationFiled: June 29, 2018Publication date: October 1, 2020Inventors: Dunja UROSEV, Yang-Chieh CHOU
-
Publication number: 20190338048Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.Type: ApplicationFiled: October 7, 2016Publication date: November 7, 2019Inventors: Dunja UROSEV, Stacy A.L. TOM-YEW, Leonard G. PRESTA, Mario SANCHES
-
Publication number: 20190085055Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: September 5, 2018Publication date: March 21, 2019Inventors: Adam Louis CORPER, Dunja UROSEV, Stacey A.L. TOM-YEW, Dustin Weyland Blue BLEILE, Thomas SPRETER VON KREUDENSTEIN, Surjit DIXIT, Paula Irene LARIO, Mario SANCHES
-
Patent number: 10077298Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: GrantFiled: November 28, 2013Date of Patent: September 18, 2018Assignee: ZYMEWORKS INC.Inventors: Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Publication number: 20180179296Abstract: The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and/or CL domains, amino acid modifications in the VH and/or VL domains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: February 14, 2018Publication date: June 28, 2018Inventors: Adam Louis CORPER, Dunja Urosev, Stacey A.L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Patent number: 9914785Abstract: The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and/or CL domains, amino acid modifications in the VH and/or VL domains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.Type: GrantFiled: November 27, 2013Date of Patent: March 13, 2018Assignee: ZYMEWORKS INC.Inventors: Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Publication number: 20170204199Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: May 29, 2015Publication date: July 20, 2017Applicant: ZYMEWORKS INC.Inventors: Mario Sanches, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A. L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
-
Publication number: 20150307594Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the C H and/or C L domains, one or more amino acid modifications in the V H and/or V L domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: November 28, 2013Publication date: October 29, 2015Inventors: Adam Louis Corper, Dunja Urosev, Stacey A.L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario
-
Publication number: 20140200331Abstract: The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and/or CL domains, amino acid modifications in the VH and/or VL domains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: November 27, 2013Publication date: July 17, 2014Applicant: Zymeworks Inc.Inventors: Adam Louis Corper, Dunja Urosev, Stacey A.L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario